@article{SteigerwaldTimmermannKuehnetal.2018,
  author    = {Steigerwald, Frank and Timmermann, Lars and K{\"u}hn, Andrea and Schnitzler, Alfons and Reich, Martin M. and Kirsch, Anna Dalal and Barbe, Michael Thomas and Visser-Vandewalle, Veerle and H{\"u}bl, Julius and van Riesen, Christoph and Groiss, Stefan Jun and Moldovan, Alexia-Sabine and Lin, Sherry and Carcieri, Stephen and Manola, Ljubomir and Volkmann, Jens},
  title     = {Pulse duration settings in subthalamic stimulation for Parkinson's disease},
  series = {Movement Disorders},
  volume    = {33},
  journal   = {Movement Disorders},
  doi       = {10.1002/mds.27238},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-239402},
  pages     = {165-169},
  year      = {2018},
  abstract  = {Background Stimulation parameters in deep brain stimulation (DBS) of the subthalamic nucleus for Parkinson's disease (PD) are rarely tested in double-blind conditions. Evidence-based recommendations on optimal stimulator settings are needed. Results from the CUSTOM-DBS study are reported, comparing 2 pulse durations. Methods A total of 15 patients were programmed using a pulse width of 30 µs (test) or 60 µs (control). Efficacy and side-effect thresholds and unified PD rating scale (UPDRS) III were measured in meds-off (primary outcome). The therapeutic window was the difference between patients' efficacy and side effect thresholds. Results The therapeutic window was significantly larger at 30 µs than 60 µs (P = ·0009) and the efficacy (UPDRS III score) was noninferior (P = .00008). Interpretation Subthalamic neurostimulation at 30 µs versus 60 µs pulse width is equally effective on PD motor signs, is more energy efficient, and has less likelihood of stimulation-related side effects. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.},
  language  = {en}
}